This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (42)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Thrombolysis  • Venous Thromboembolism  • Cardiovascular System  • Quality of Care  • Evidence-Based Medicine  • Alert me on articles by topic  Social Bookmarking   What's this?

A Clinical Outcome–Based Meta-analysis

Giancarlo Agnelli, MD; Cecilia Becattini, MD; Timo Kirschstein, MD

Arch Intern Med. 2002;162:2537-2541.

Background  In patients with acute pulmonary embolism, thrombolysis results in a more rapid resolution of pulmonary emboli than heparin treatment. Whether this advantage results in an improved clinical outcome is unclear. We sought to perform a clinical outcome–based meta-analysis of studies comparing thrombolytic and heparin treatment in patients with pulmonary embolism.

Methods  Data concerning adverse outcome events (death, recurrent pulmonary embolism, and major bleeding events) were extracted from the identified randomized studies.

Results  A total of 56 (23.2%) of 241 patients treated with thrombolytic agents in 9 randomized trials experienced an adverse outcome event compared with 57 (25.9%) of 220 patients treated with heparin (relative risk [RR], 0.9; 95% confidence interval [CI], 0.57-1.32). In the thrombolysis group, 11 patients (4.6%) died compared with 17 (7.7%) in the heparin group (RR, 0.59; 95% CI, 0.27-1.25). Thirty-one patients (12.9%) undergoing thrombolysis had a major bleeding episode compared with 19 patients (8.6%) treated with heparin (RR, 1.49; 95% CI, 0.85-2.81). Five fatal bleeding episodes (2.1%) occurred in the thrombolysis group and none in the heparin group. Six studies provided data on recurrent pulmonary embolism. A recurrence occurred in 14 (6.6%) of 214 patients treated with thrombolytic agents and in 22 (10.9%) of 201 patients treated with heparin (RR, 0.60; 95% CI, 0.29-1.15). Recurrence and/or death occurred in 25 (10.4%) of 241 and in 38 (17.3%) of 220 patients treated with thrombolytic agents and heparin, respectively (RR, 0.55; 95% CI, 0.33-0.96; P = .03).

Conclusions  In patients with pulmonary embolism, thrombolysis had a lower composite end point of death/recurrence than heparin treatment. Excessive bleeding is the trade-off for improved efficacy. A comparative clinical outcome trial of thrombolysis and heparin treatment is warranted in patients with pulmonary embolism and selected for high risk of death and/or recurrence and low risk of bleeding.

From the Department of Internal Medicine, Section of Internal and Cardiovascular Medicine, University of Perugia, Perugia, Italy.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

The Uncertain Role of Thrombolytic Therapy in the Treatment of Pulmonary Embolism
James E. Dalen
Arch Intern Med. 2002;162(22):2521-2523.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Thrombolytic Therapy and Mortality in Patients With Acute Pulmonary Embolism
Ibrahim et al.
Arch Intern Med 2008;168:2183-2190.
ABSTRACT | FULL TEXT  

Thrombolytic Therapy and Mortality in Patients With Acute Pulmonary Embolism--Invited Commentary
Brotman and Streiff
Arch Intern Med 2008;168:2191-2192.
FULL TEXT  

Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC)
Authors/Task Force Members et al.
Eur Heart J 2008;29:2276-2315.
FULL TEXT  

Expedient pulmonary embolectomy for acute pulmonary embolism: improved outcomes
Ahmed et al.
ICVTS 2008;7:591-594.
ABSTRACT | FULL TEXT  

Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Kearon et al.
Chest 2008;133:454S-545S.
ABSTRACT | FULL TEXT  

Haemodynamically unstable pulmonary embolism in the RIETE Registry: systolic blood pressure or shock index?
Otero et al.
Eur Respir J 2007;30:1111-1116.
ABSTRACT | FULL TEXT  

Efficacy of thrombolytic agents in the treatment of pulmonary embolism
Capstick and Henry
Eur Respir J 2005;26:864-874.
ABSTRACT | FULL TEXT  

When should we thrombolyse patients with pulmonary embolism? A systematic review of the literature
Harris and Meek
Emerg. Med. J. 2005;22:766-771.
ABSTRACT | FULL TEXT  

Thrombolysis for Pulmonary Embolism in Patients With Right Ventricular Dysfunction: Con
Thabut and Logeart
Arch Intern Med 2005;165:2200-2203.
FULL TEXT  

Review: no evidence exists that thrombolysis is better than heparin for reducing the risk of recurrent pulmonary embolism and death
van den Berg
Evid. Based Nurs. 2005;8:52-52.
FULL TEXT  

Thrombolysis Compared With Heparin for the Initial Treatment of Pulmonary Embolism: A Meta-Analysis of the Randomized Controlled Trials
Wan et al.
Circulation 2004;110:744-749.
ABSTRACT | FULL TEXT  

Prognostic Value of Echocardiographically Assessed Right Ventricular Dysfunction in Patients With Pulmonary Embolism
ten Wolde et al.
Arch Intern Med 2004;164:1685-1689.
ABSTRACT | FULL TEXT  

Low-Molecular-Weight Heparin Compared with Intravenous Unfractionated Heparin for Treatment of Pulmonary Embolism: A Meta-Analysis of Randomized, Controlled Trials
Quinlan et al.
ANN INTERN MED 2004;140:175-183.
ABSTRACT | FULL TEXT  

OTHER ARTICLES NOTED (24 Jan 03 to 18 Apr 03)
Evid. Based Nurs. 2003;6:e1-12.
FULL TEXT  

British Thoracic Society guidelines for the management of suspected acute pulmonary embolism
Thorax 2003;58:470-483.
FULL TEXT  

The Uncertain Role of Thrombolytic Therapy in the Treatment of Pulmonary Embolism
Dalen
Arch Intern Med 2002;162:2521-2523.
FULL TEXT